PMID- 32400119
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1524-4741 (Electronic)
IS  - 1075-122X (Linking)
VI  - 26
IP  - 6
DP  - 2020 Jun
TI  - HER2 testing across practices-Have we come to a consensus on the ideal method of 
      testing? A systematic literature review.
PG  - 1185-1188
LID - 10.1111/tbj.13867 [doi]
AB  - Human epidermal growth factor (HER2) is an oncogene that codes for HER2 protein. 
      The gene is amplified, and protein is overexpressed in 20% of patients and 
      carries a poor prognosis. HER2-positive tumors tend to be more aggressive and 
      highly proliferative. In 2006, trastuzumab, a monoclonal antibody targeting HER2, 
      was approved for use with chemotherapy as an adjuvant treatment for women with 
      HER2-positive breast cancer. The drug has shown improved survival rates for women 
      with HER2-positive breast cancer. As promised for survival in HER2-positive 
      patients continues with new research, and as novel drug approvals emerge, HER2 
      assessment plays a significant role in adjuvant and in metastatic setting. HER2 
      assays approved by the US Food and Drug administration include 
      immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and bright 
      field dual in situ hybridization (DISH). Accuracy of HER2 testing across 
      laboratories has an impact on treatment as false-negative testing can deprive the 
      patients of trastuzumab therapy. The current review will focus on the variability 
      of HER2 testing across laboratories and the potential impact on treatment.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Nassar, Aziza
AU  - Nassar A
AUID- ORCID: 0000-0002-6678-9329
AD  - Department of Pathology and Laboratory Medicine, Mayo Clinic, Jacksonville, 
      Florida, USA.
FAU - Pooja, Advani
AU  - Pooja A
AD  - Department of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida, USA.
FAU - Chivukula, Mamatha
AU  - Chivukula M
AD  - Department of Pathology and Laboratory Medicine, Mills-Peninsula Hospital, 
      Burlingame, California, USA.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20200512
PL  - United States
TA  - Breast J
JT  - The breast journal
JID - 9505539
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Biomarkers, Tumor
MH  - *Breast Neoplasms/drug therapy/genetics
MH  - Consensus
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Receptor, ErbB-2/genetics
MH  - Trastuzumab/therapeutic use
OTO - NOTNLM
OT  - FISH
OT  - HER2
OT  - immunohistochemistry
OT  - trastuzumab
EDAT- 2020/05/14 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/14 06:00
PHST- 2020/03/16 00:00 [received]
PHST- 2020/03/18 00:00 [accepted]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/14 06:00 [entrez]
AID - 10.1111/tbj.13867 [doi]
PST - ppublish
SO  - Breast J. 2020 Jun;26(6):1185-1188. doi: 10.1111/tbj.13867. Epub 2020 May 12.